P2.04-26 Interim Results from a Phase I/II Trial of Nivolumab in Combination with CIMAvax-EGF as Second-Line Therapy in Advanced NSCLC
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.08.1250
Abstract: since we will be able to compare our results with the once published previously. Method: We have reviewed 129 patients with NSCLC, advanced or recurrent stages, treated with nivolCutumab either in second and subsequent lines… read more here.
Keywords: response; results phase; treatment; interim results ... See more keywords
Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-111144
Abstract: Context. The prognostic value of gene mutations in older AML patients (pts) treated intensively remains unclear. Only one study has explored the role of mutation patterns determined by NGS in older AML pts prospectively treated… read more here.
Keywords: treated intensively; risk; aml patients; adv cytogenetics ... See more keywords
Recurrent Stroke: The Role of Thrombophilia in a Large International Pediatric Stroke Population
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-118914
Abstract: OBJECTIVE: Risk factors for arterial ischemic stroke (AIS) in children are multiple and include cardiac disease, vasculopathy, and prothrombotic risk factors (PR). The relevance of these factors to a second AIS event is incompletely understood.… read more here.
Keywords: pediatric stroke; recurrent ais; recurrence; median months ... See more keywords
Precision medicine and actionable alterations in lung cancer: A single institution experience
Sign Up to like & getrecommendations! Published in 2020 at "PLoS ONE"
DOI: 10.1371/journal.pone.0228188
Abstract: Objectives Oncology has become more reliant on new testing methods and a greater use of electronic medical records, which provide a plethora of information available to physicians and researchers. However, to take advantage of vital… read more here.
Keywords: actionable alterations; medicine; precision medicine; median months ... See more keywords
Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2020.01173
Abstract: Background: Serum tumor markers carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cytokeratin 19 fragment (CYFRA21-1) and squamous-cell carcinoma-related antigen (SCC-Ag) are routinely used for monitoring the response to chemotherapy or targeted therapy in advanced-stage non-small… read more here.
Keywords: tumor markers; patients treated; serum tumor; cell ... See more keywords
Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14020324
Abstract: Simple Summary Sarcomas of the liver are a rare and aggressive group of malignancies for which surgery is the preferred treatment modality even though most patients are not surgical candidates and receive chemotherapy with poor… read more here.
Keywords: sarcomas; metastatic primary; median months; primary hepatic ... See more keywords